 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ:SYRS, a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC Orsenix all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide ATO. SY-2101 represents a strategic opportunity to leverage Syros expertise and capabilities to advance its growing footprint in hematologic disorders, with a targeted clinical 